Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUNLUN
2020-001001-22Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Durvalumab + definitive chemoradiation with Placebo + definitive chemoradiation (2 arms). Primary endpoint: Progression-free survival. Started Oct 2020; status: terminated.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2020-001001-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001001-22.